Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection

American Journal of Hematology

Volumn 80, Issue 1, 2005, Pages 64-69

  Okano, Motohiko ^a,l   Kawa, Keisei ^b   Kimura, Hiroshi ^c   Yachie, Akihiro ^d   Wakiguchi, Hiroshi ^e   Maeda, Akihiko ^e   Imai, Shosuke ^e   Ohga, Shouichi ^f   Kanegane, Hirokazu ^g   Tsuchiya, Shigeru ^h   Morio, Tomohiro ⁱ   Mori, Masaaki ^j   Yokota, Shumpei ^j   Imashuku, Shinsaku ^k  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^e KOCHI MEDICAL SCHOOL   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g UNIVERSITY OF TOYAMA   (Japan)

^h TOHOKU UNIVERSITY   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^j YOKOHAMA CITY UNIVERSITY   (Japan)

^k Takasago seibu Hospital   (Japan)

^l HOKKAIDO INSTITUTE OF PUBLIC HEALTH   (Japan)

more..

Author keywords

Chronic active Epstein Barr virus infection; Diagnosis; Guidelines

Indexed keywords

ANTIVIRUS AGENT; CORTICOSTEROID; CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INTERLEUKIN 2;

ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; CHRONIC ACTIVE EPSTEIN BARR VIRUS INFECTION; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; EPSTEIN BARR VIRUS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOLOGICAL TECHNIQUE; JAPAN; LABORATORY DIAGNOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; VIRUS INFECTION;

ACUTE DISEASE; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MOLECULAR BIOLOGY;

EID: 24344435023     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20398     Document Type: Review

References (51)

1. Macsween KF, Crawford DH. Epstein-Barr virus-recent advances. Lancet Infect Dis 2003;3:131-140.
2. Okano M. Haematological associations of Epstein-Barr virus infection. Bailliere's Clin Haematol 2000;13:199-214.
3. Horwitz CA, Henle W, Henle G, Schmitz H. Clinical evaluation of patients with infectious mononucleosis and development of antibodies to the R component of the Epstein-Barr virus-induced early antigen complex. Am J Med 1975;58:330-338.
4. Tobi M, Ravid Z, Feldman-Weiss V, et al. Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection. Lancet 1982;i:61-63.
5. Dubois RE, Seely JK. Brus I, et al. Chronic mononucleosis syndrome. South Med J 1984;77:1376-1382.
6. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence of active Epstein-Barr virus infection in patients with unexplained illness: elevated anti-early antigen antibodies. Ann Intern Med 1985;102:1-6.
7. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985;102:7-16.
8. Rickinson AB. Chronic, symptomatic Epstein-Barr virus infections. Immunol Today 1986;7:13-14.
9. Virelizier JL, Lenoir G, Griscelli C. Persistent Epstein-Barr virus infection in a child with hypergammaglobulinemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet 1978;ii:231-234.
10. Straus SE. The chronic mononucleosis syndrome. J Infect Dis 1988;157:40 5-412.
11. Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT. Severe chronic active Epstein-Barr virus infection syndrome. Clin Microbiol Rev 1991;4:129-135.
12. Jones JF, Shurin S. Abramowsky C, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infection. N Engl J Med 1988;318:733-741.
13. Kanegane H, Bhatia K, Gutierrez M, et al. A syndrome of peripheral blood T-cell infection with Epstein-Barr virus (EBV) followed by EBV-positive T cell lymphoma. Blood 1998;91:2085-2091.
14. Imai S, Sugiura M, Oikawa O, et al. Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection. Blood 1996;87:1446-1457.
15. Okano M. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. Crit Rev Oncol/Hematol 2002;44:273-282.
16. Kawa K, Okamura T, Yasui M, Sato E, Inoue M. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Crit Rev Oncol/Hematol 2002;44:251-257.
17. Yachie A, Kanegane H, Kasahara Y. Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative diseases. Semin Hematol 2003;40:124-132.
18. Suzuki K, Oshima K, Karube K, et al. Clinicopathological states of Epstein-Barr virus-associated T/NK-cell lymphoproliferative disorders (severe chronic active EBV infection) of children and young adults. Int J Oncol 2004;24:1165-1174.
19. Kimura H, Hoshino Y, Kanegane H, et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 2001;98:280-286.
20. Kimura H, Morishima T, Kanegane H, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 2003;187:527-533.
21. Ishihara S, Okada S, Wakiguchi H, Kurashige T, Morishima T, Kawa-Ha K. Chronic active Epstein-Barr virus infection in children in Japan. Acta Paediatr 1995;84:1271-1275.
22. Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest 1993;92:1444-1450.
23. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 1999;93:1869-1874.
24. Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD-3 negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989;84:51-55.
25. Ishihara S, Tawa A, Yumura-Yagi K, et al. Clonal T-cell lymphoproliferation containing Epstein-Barr (EB) virus DNA in a patient with chronic active EB virus infection. Jpn J Cancer Res 1989;80:94-100.
26. Ishihara S, Ohshima K, Tokura Y, et al. Hypersensitivity to mosquito bites conceals clonal lymphoproliferation of Epstein-Barr viral DNA-positive natural killer cells. Jpn J Cancer Res 1997;88:82-87.
27. Tokura Y, Ishihara S, Ohshima K, et al. Severe mosquito bite hypersensitivity, natural killer cell leukemia, latent or chronic active Epstein-Barr virus infection and hydroa vacciniforme-like eruption. Br J Dermatol 1998;138:905-906.
28. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999;37:132-136.
29. Maeda A, Wakiguchi H, Yokoyama W, Hisakawa H, Tomoda T, Kurashige T. Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. J Infect Dis 1999;179:1012-1015.
30. Patel S, Zuckerman M, Smith M. Real-time quantitative PCR of Epstein-Barr virus BZLF1 DNA using the LightCycler. J Virol Methods 2003;109:227-233.
31. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001;98:1882-1888.
32. Habeshaw G, Yao QY, Bell AI, Morton D, Rickinson AB. Epstein-Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt's lymphoma reflect virus strains prevalent in different geographic areas. J Virol 1999;73:965-975.
33. Kikuta H, Nakanishi M, Sakiyama Y, Matsumoto S. Chronic active Epstein-Barr virus (EBV) infection is associated with clonotypic intracellular terminal regions of the EBV. J Infect Dis 1989;160:546-547.
34. Yoshioka M, Ishiguro N, Ishiko H, Ma X, Kikuta H, Kobayashi K. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. J Gen Virol 2001;82:2385-2392.
35. Taketani T, Kikuchi A, Inatomi J, et al. Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2002;29:531-533.
36. Oshima K, Suzumiya J, Sugihara M, Nagafuchi S, Ohga S, Kikuchi M. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Pathol Int 1998;48:934-943.
37. Oshima K, Suzumiya J, Ohga S, Ohgami A, Kikuchi M. Integrated Epstein-Barr virus (EBV) and chromosomal abnormality in chronic active EBV infection. Int J Cancer 1997;71:943-947.
38. Zhang Y, Nagata H, Ikeuchi T. et al. Common cytological and cytogenetic features of Epstein-Barr virus (EBV)-positive natural killer (NK) cells and cell lines derived from patients with nasal T/ NK-cell lymphomas, chronic active EBV infection and hydroa vacciniforme-like eruptions. Br J Haematol 2003;121:805-814.
39. Katano H, Ali MA, Patera AC, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its mutation. Blood 2004;103:1244-1252.
40. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000;96:3118-3125.
41. Mitarnun W, Suwiwat S, Pradutkanchana J, et al. Epstein-Barr virus-associated peripheral T-cell and NK-cell proliferative diseases/lymphoma: clinicopathologic, serologic, and molecular analysis. Am J Hematol 2002;70:31-38.
42. Au W-Y, Pang A, Choy C, Chim CS, Kwong Y-L. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243-249.
43. Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology 2001:259-281.
44. Ichima K, Kagami Y, Suzuki R, et al. Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites. Pathol Int 2003;53:333-344.
45. Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Tosato G. Viral interleukin-10 in chronic active Epstein-Barr virus infection. J Infect Dis 1997;176:254-257.
46. Ohga S, Nomura A, Takada H, et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J Infect Dis 2001;183:1-7.
47. Tabiasco J, Vercellone A, Meggetto F, Hudrisier D, Brousset P, Fournie J-J. Acquisition of viral receptor by NK cells through immunological synapse. J Immunol 2003;170:5993-5998.
48. Isobe Y, Sugimoto K, Yang L, et al. Epstein-Barr virus infection of human natural killer cell lines and peripheral blood natural killer cells. Cancer Res 2004;64:2167-2174.
49. Okano M. Therapeutic approaches for severe Epstein-Barr virus infection. Pediatr Hematol Oncol 1997;14:109-119.
50. Savoldo B, Hhuls AH, Liu Z, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002;100:4059-4066.
51. Okamura T. Hatsukawa Y, Arai H, Inoue M, Kawa K. Blood stem-cell transplantation for chronic active Epstein-Barr virus lymphoproliferation. Lancet 2000;356:223-224.